Pelican Impex S.R.L.
- Address
- lock Available on a paid plan
Neoplasms
The Medical Oncology Department at Pelican Impex S.R.L. conducts research focused on a range of solid tumours, including advanced non‑small cell lung cancer, metastatic breast cancer, and gastrointestinal cancers.
- Lung cancer immunotherapy combinations
- Targeted therapies for KRAS/NRAS wild‑type colorectal cancer
- HER2‑targeted regimens in gastric and gastro‑esophageal junction cancer
- Novel agents for cancer‑associated cachexia
These studies aim to improve treatment effectiveness and explore new therapeutic options for patients with aggressive malignancies.
Digestive System Diseases
Research at the site addresses inflammatory bowel conditions such as ulcerative colitis and Crohn's disease, evaluating innovative biologic and small‑molecule therapies.
- Long‑term efficacy of anti‑IL‑23 agents
- Oral therapies for moderate to severe disease activity
- Safety assessments of maintenance treatment strategies
The goal is to provide patients with more durable remission and better quality of life.
Virus Diseases
The centre investigates chronic viral infections, notably hepatitis B, through antiviral strategies aimed at functional cure.
- RNA‑based therapeutics targeting hepatitis B surface antigen
- Combination approaches with nucleos(t)ide analogues
- Biomarker‑driven assessment of viral suppression
These trials seek to reduce viral load and achieve sustained remission without long‑term medication.
Nutritional and Metabolic Diseases
Studies explore metabolic complications linked to cancer and chronic illness, including cancer‑associated cachexia and metabolic dysregulation.
- Agents modulating muscle wasting pathways
- Nutritional interventions combined with oncologic therapy
- Evaluation of metabolic biomarkers for treatment response
The research aims to enhance patient stamina and overall health during intensive treatments.
Metabolism
The department conducts investigations into fundamental metabolic processes that influence tumour growth and treatment response.
- Cellular energy pathways in solid tumours
- Impact of metabolic inhibitors on disease progression
- Correlation of metabolic profiles with therapeutic outcomes
Understanding these mechanisms supports the development of more precise anticancer strategies.
Physiological Processes
Research includes the study of physiological responses to therapy, such as immune activation and tissue repair, particularly in lung and gastrointestinal cancers.
- Immune checkpoint modulation after chemoradiation
- Biomarkers of treatment‑induced inflammation
- Recovery of organ function post‑therapy
These efforts aim to optimize patient resilience and minimize adverse effects.
Cardiovascular Diseases
Although primarily an oncology hub, the site also monitors cardiovascular health in patients receiving cancer therapies, focusing on safety and risk mitigation.
- Cardiotoxicity surveillance during targeted treatment
- Management of hypertension linked to therapy
- Integration of cardiac biomarkers in trial protocols
This complementary research helps ensure comprehensive care for participants throughout their treatment journey.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Abivax1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pelican Impex S.R.L.
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis. | Celltrion Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2018-03-21 | 2025-06-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.